Evaluation of Alpha 1-Antitrypsin and the Levels of mRNA Expression of Matrix Metalloproteinase 7, Urokinase Type Plasminogen Activator Receptor and COX-2 for the Diagnosis of Colorectal Cancer

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Bujanda, Luis ^a   Sarasqueta, Cristina ^a   Cosme, Angel ^a   Hijona, Elizabeth ^a   Enríquez Navascués, José M ^a   Placer, Carlos ^a   Villarreal, Eloisa ^a   Herreros Villanueva, Marta ^a   Giraldez, María D ^b   Gironella, Meritxell ^b   Balaguer, Francesc ^b   Castells, Antoni ^b  

^a HOSPITAL DONOSTIA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; CARBONATE DEHYDRATASE; CARCINOEMBRYONIC ANTIGEN; COMPLEMENT COMPONENT C3A; CYCLOOXYGENASE 2; CYTOKERATIN 20; GUANYLATE CYCLASE; HERMES ANTIGEN; MATRILYSIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR; SURVIVIN; TETRANECTIN; THYMIDYLATE SYNTHASE; TUMOR MARKER; UROKINASE RECEPTOR; VASCULOTROPIN;

AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC;

AGED; ALPHA 1-ANTITRYPSIN; COLONOSCOPY; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DNA PRIMERS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, MESSENGER; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84871792098     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051810     Document Type: Article

References (29)

1. La situación del cáncer en España. Spanish Ministry of Health and Consumer Affairs. Madrid. 2005.
2. Greenlee R, Hill-Harmon MB, Murria T, Thun M, (2001) Cancer statistics. Cancer J Clinic 51: 15-36.
3. Bujanda L, Sarasqueta C, Hijona E, Hijona L, Cosme A, et al. (2010) Colorectal cancer prognosis twenty years later. World J Gastroenterol. 16: 862-867.
4. Ahlquist DA, (2010) Molecular detection of colorectal neoplasia. Gastroenteroloy 138: 2127-2129.
5. Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, et al. (2005) Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol 36: 170-179.
6. Bustin SA, Mueller R, (2006) Real-time transcription PCR and the detection of occult disease in colorectal cancer. Mol Aspects Med 27: 192-223.
7. Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M,et al. Messenger RNA expression of COX-2 and angiogenic factors in primary colorectal cancer and corresponding liver metastasis. Int J Oncol 34: 1147-53.
8. Hurst NG, Stocken DD, Wilson S, Keh C, Wakelam MJ, et al. (2007) Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 97: 971-977.
9. Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, et al. (2008) VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res 28: 3865-3867.
10. Bernacka K, Kurryliszyn-Moskal A, Sierakowski S, (1988) The levels of alpha 1-antitrypsin and alpha 1-antichymotrypsin in the sera of patients with gastrointestinal cancer during diagnosis. Cancer 62: 1188-1193.
11. Habermann JK, Roblick UJ, Luke BT, Prieto DA, Finlay WJJ, et al. (2006) Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 131: 1020-1029.
12. Sivridis E, Koukourakis MI, (2003) Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis 18: 418-422.
13. Grabarczyk E, Szaflarska-Popławska A, Góralczyk K, Adamska I, Rość D, (2007) Urokinase plasminogen activator (u-PA) and urokinase type plasminogen activator receptor (u-PAR) in children with ulcerative colitis. Med Wieku Rozwoj 11: 41-44.
14. Begum FD, Høgdall E, Kjaer SK, Blaakaer J, Christensen IJ, et al. (2009) Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Gynecol Oncol 113: 221-227.
15. Arvanitis DL, Kamper EF, Kopeikina L, Stavridou A, Sgantzos MN, et al. (2002) Tetranectin expression in gastric adenocarcinomas. Histol Histopathol 17: 471-475.
16. American Joint Committee on Cancer: Manual for staging of cancer 5th ed. Philadelphia, JB Lippincott, 1997.
17. Ishigami S, Sakamoto A, Uenosono Y, Nakajo A, Okumura H, et al. (2008) Carcinoembryonic antigen messenger RNA expression in blood can predict relapse in gastric cancer. J Surg Res 148: 205-209.
18. Setoyama T, Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, et al. (2006) Carcinoembryonic antigen messenger RNA expression in blood predicts recurrence in esophageal cancer. Clin Cancer Res 12: 5972-5977.
19. Sadahiro S, Suzuki T, Maeda Y, Yurimoto S, Yasuda S, et al. (2007) Detection of carcinoebryonic antigen messenger RNA-expressing cells in perpheral blood 7 days after curative surgery is a novel prognostic factor in colorectal cancer. Ann Surg Oncol 14: 1092-1098.
20. Høgdall CK, Christensen IJ, Stephens RW, Sørensen S, Nørgaard-Pedersen B, et al. (2002) Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA. APMIS. 110: 630-638.
21. Pyke C, Dristensen P, Ralfkiaer E, Grondalhl-Hansen J, et al. (1991) Urokinase-type plasminogen activator is expressed in stromal and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067.
22. Begum FD, Høgdall CK, Kjaer SK, Christensen L, Blaakaer J, et al. (2004) The prognostic value of plasma soluble urokinase plasminogen activator receptor (uPAR) levels in stage III ovarian cancer patients. Anticancer Res. 24: 1981-1985.
23. Stephens RW, Nielesen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, et al. (2010) Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. JNCI 91: 869-974.
24. Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, et al. (2008) Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis. Int J Oncol 33: 1257-1262.
25. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, et al. (2006) Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 94: 1898-1905.
26. Stamatiadis AP, Toumanidou MS, Vyssoulis GP, Mnouras AJ, Apostolidis NS, (1990) Value of serum acute-phase reactant proteins and carcinoembryonic antigen in the preoperative staging of colorectal cancer. Cancer 65: 2055-2057.
27. Hsu PI, Chen CH, Hsieh CS, Chang WC, Lai KH, et al. (2007) α1-atnitrypsin precursor in gastric juice is a novel biomarker for gastric cancer and ulcer. Clin Cancer Res 13: 876-883.
28. Lee K, Kye M, Jang JS, Lee OJ, Kim T, et al. (2004) Proteomic analysis revealed a strong association of a high level of α1-antitrypsin in gastric juice with gastric cancer. Proteomics 4: 3343-3352.
29. Mollnes TE, Garred P, Bergseth G, (1998) Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol 123: 484-488.